107 related articles for article (PubMed ID: 28306620)
1. Diagnostic performance of a novel dedicated breast PET scanner with C-shaped ring detectors.
Nakamoto R; Nakamoto Y; Ishimori T; Nishimatsu K; Miyake KK; Kanao S; Iima M; Toi M; Togashi K
Nucl Med Commun; 2017 May; 38(5):388-395. PubMed ID: 28306620
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation.
Iima M; Nakamoto Y; Kanao S; Sugie T; Ueno T; Kawada M; Mikami Y; Toi M; Togashi K
J Nucl Med; 2012 Oct; 53(10):1534-42. PubMed ID: 22933819
[TBL] [Abstract][Full Text] [Related]
3. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT.
Nishimatsu K; Nakamoto Y; Miyake KK; Ishimori T; Kanao S; Toi M; Togashi K
Eur J Radiol; 2017 May; 90():138-145. PubMed ID: 28583624
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PET/CT with Sequential PET/MRI Using an MR-Compatible Mobile PET System.
Nakamoto R; Nakamoto Y; Ishimori T; Fushimi Y; Kido A; Togashi K
J Nucl Med; 2018 May; 59(5):846-851. PubMed ID: 29097407
[TBL] [Abstract][Full Text] [Related]
5. A second-generation virtual-pinhole PET device for enhancing contrast recovery and improving lesion detectability of a whole-body PET/CT scanner.
Jiang J; Li K; Wang Q; Puterbaugh K; Young JW; Siegel SB; O'Sullivan JA; Tai YC
Med Phys; 2019 Sep; 46(9):4165-4176. PubMed ID: 31315157
[TBL] [Abstract][Full Text] [Related]
6. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
8. Performance evaluation of a high resolution dedicated breast PET scanner.
García Hernández T; Vicedo González A; Ferrer Rebolleda J; Sánchez Jurado R; Roselló Ferrando J; Brualla González L; Granero Cabañero D; Del Puig Cozar Santiago M
Med Phys; 2016 May; 43(5):2261. PubMed ID: 27147338
[TBL] [Abstract][Full Text] [Related]
9. Whole-body bone SPECT in breast cancer patients: the future bone scan protocol?
Abikhzer G; Gourevich K; Kagna O; Israel O; Frenkel A; Keidar Z
Nucl Med Commun; 2016 Mar; 37(3):247-53. PubMed ID: 26528786
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
12. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer.
Sakaguchi R; Kataoka M; Kanao S; Miyake KK; Nakamoto Y; Sugie T; Toi M; Mikami Y; Togashi K
Ann Nucl Med; 2019 Aug; 33(8):570-578. PubMed ID: 31115856
[TBL] [Abstract][Full Text] [Related]
13. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
[TBL] [Abstract][Full Text] [Related]
14. A dedicated breast-PET/CT scanner: Evaluation of basic performance characteristics.
Raylman RR; Van Kampen W; Stolin AV; Gong W; Jaliparthi G; Martone PF; Smith MF; Sarment D; Clinthorne NH; Perna M
Med Phys; 2018 Apr; 45(4):1603-1613. PubMed ID: 29389017
[TBL] [Abstract][Full Text] [Related]
15. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
16. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
17. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses.
Drzezga A; Souvatzoglou M; Eiber M; Beer AJ; Fürst S; Martinez-Möller A; Nekolla SG; Ziegler S; Ganter C; Rummeny EJ; Schwaiger M
J Nucl Med; 2012 Jun; 53(6):845-55. PubMed ID: 22534830
[TBL] [Abstract][Full Text] [Related]
18. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
[TBL] [Abstract][Full Text] [Related]
19. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
20. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
